Clinical trial · Observational
Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System
Clinical Product Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System
NCT01067755CI-TRIAL-00003140unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the role of the LungPoint VBN System in the bronchoscopic access to a target location. The evaluation will explore: * Ability of the system to guide a user to one or more target site(s) * Ease of use of the system (assessment of the user interface) * Incremental value brought by the use of the system to the successful completion of a case.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasm | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Bronchoscopy, lung neoplasm
- description
- Patients who have been recommended for bronchoscopy for the purpose of obtaining a biopsy sample of a central or peripheral pulmonary lesion, diagnosing mediastinal or hilar lymphadenopathy or for lung fiducial placement.
- interventionNames
- Device: LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)
Primary outcomes (1)
- measure
- Evidence that LungPoint VBN has a clear role in targeted bronchoscopic procedures
- timeFrame
- Immediate post-operative (day 0)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subject has provided Informed Consent * Subject is scheduled for bronchoscopy for the purpose of diagnosing: a central or peripheral pulmonary nodule or mass, infiltrative disease, mediastinal or hilar lymphadenopathy, or placing fiducial markers. * Subject has a CT scan that is consistent with high-resolution specifications Exclusion Criteria: * Patients less than 18 years of age. * Any patient that the Investigator feels is not appropriate for this study for any reason.
References
Publications (1)
- DERIVEDEberhardt R, Kahn N, Gompelmann D, Schumann M, Heussel CP, Herth FJ. LungPoint--a new approach to peripheral lesions. J Thorac Oncol. 2010 Oct;5(10):1559-63. doi: 10.1097/JTO.0b013e3181e8b308. PMID 20802352